

Polysaccharides and Natural Gums for Colon Drug Delivery

Mohit Khandelwal*, Ankit Ahlawat and Ram Singh

Submitted 2011.08.30. Accepted for publication 2011.12.14.

The site-specific delivery of the drugs to the target sites has the potential to reduce the side effects and improved the pharmacological response. The colon drug targeting is also exploited for systemic delivery of active drugs. For colonic drug delivery, many physiological barriers must be overcome, the major one being absorption or degradation of the active drugs in the upper part of the GIT-Tract. Natural polymers particularly in the form of microspheres, have an important role in the before they will have widespread use in clinical situations. Among these issues are better understanding of the kinetics of drug release; more effective ways to control burst phenomena; greater understanding of drug-polymer interactions and their effect on shelf life stability; additional animal studies to determine local tissue response, biodegradation rates, and metabolic rate. Well-designed Clinical studies to assess efficacy in relation to current therapies.

Keyword: Polysaccharides, Colon Drug Delivery, Pectin

INTRODUCTION: The colon is attracting interest as a site where poorly absorbed drug molecule may have an improved bioavailability. This region of the colon is recognized as having a somewhat less hostile environment with less diversity and intensity of activity than the stomach and small intestine. Oral delivery of drugs to the colon is valuable in the treatment of diseases of colon (ulcerative colitis, Crohn's disease, carcinomas and infections) whereby high local concentration can be achieved while minimizing side effects that occur because of release of drugs in the upper GIT or unnecessary systemic absorption. The colon is rich in

lymphoid tissue, uptake of antigens into the mast cells of the colonic mucosa produces rapid local production of antibodies and this helps in efficient vaccine delivery. The colon has a longer retention time and appears highly responsive to agents that enhance the absorption of poorly absorbed drugs. The simplest method for targeting of drugs to the colon is to obtain slower release rates or longer release periods by the application of thicker layers of conventional enteric coatings or extremely slow releasing matrices.

Pectin: Pectins are nonstarch linear polysaccharides that consist of α -1, 4 D-galacturonic acid and 1, 2 D-rhamnose with D-galactose and D-arabinose side chains having average molecular weights between 50,000 to 150,000. Pectin tends to produce lower viscosities

Corresponding Author's Contact information:
Mohit Khandelwal*
Gayatri College of Pharmacy, Sambalpur, Odisha, India
E-mail: Mohit.crra@gmail.com

than other plant gums. It is refractory to host gastric and small intestinal enzymes but is almost completely degraded by the colonic bacterial enzymes to produce a series of soluble oligalactorunates¹. Depending on the plant source and preparation; they contain varying degrees of methyl ester substituents². Micro particulate polymeric delivery systems have been suggested as a possible approach to improve the low bioavailability characteristics shown by standard ophthalmic vehicles (collyria). In this context pectin microspheres of piroxicam were prepared by the spray drying technique. In vivo tests in rabbits with dispersions of piroxicam-loaded microspheres also indicated a significant improvement of piroxicam bioavailability in the aqueous humour (2.5-fold) when compared with commercial piroxicam eye drops^{3, 4}. In vivo gamma scintigraphic studies confirmed the in vitro findings. In all the volunteers, the pectin-coated tablets disintegrated in the colon indicating that site-specificity had been achieved and illustrating the potential of a colonic drug delivery system utilizing pectin. This necessitates the development of such derivatives of pectin, which were less water-soluble but were having the capability to be degraded by the colonic microflora. Calcium pectinate, the insoluble salt of pectin was used for colon targeted drug delivery of indomethacin by Rubeinstein et al.⁵. The results suggest that the pectin-chloroquine patch matrix preparation has potential applications for the transdermal delivery of chloroquine and perhaps in the management of malaria. Calcium pectinate nanoparticles to deliver insulin were prepared as a potential colonic delivery system by ionotropic gelation⁶.

Chitosan: Chitosan is a high molecular weight polycationic polysaccharide derived from naturally occurring chitin by alkaline deacetylation. Chemically, it is a poly (N-

glucosamine). Chitosan has favorable biological properties such as nontoxicity, biocompatibility and biodegradability. Similar to other polysaccharides it also undergoes degradation by the action of colonic microflora and hence poses its candidature for colon targeted drug delivery. Therapeutic effect of R-68070, a new thromboxane synthetase inhibitor on 2,4,6 trinitrobenzene sulfonic acid sodium salt induced ulcerative colitis was studied using chitosan capsules to achieve its colon-specific drug delivery in rats⁷. A multiparticulate system of chitosan hydrogel beads has been investigated for colon-specific drug delivery of macromolecules using fluorescein isothiocyanate-labeled bovine serum albumin as a model protein. The hydrogel bead was formed by polyelectrolyte complexation of chitosan with its counter ion, tripolyphosphate. The protein release experiments were carried out in vitro under different conditions to simulate the pH and times likely to be encountered during intestinal transit to the colon. The results shown that the hydrogel beads were degraded by rat cecal and colonic enzymes, resulting in a marked acceleration in the release of protein⁸. Chitosan microspheres are used to provide controlled release of many drugs and to improve the bioavailability of degradable substances such as protein, as well as to improve the uptake of hydrophilic substances across the epithelial layers. These microspheres are being investigated both for parenteral and oral drug delivery⁹.

GUMS:

Gums are translucent and amorphous substances produced by the plants. Usually pathological products, gums are produced when the plant is growing under unfavorable conditions or when injured. Gums are plant hydrocolloids and may be anionic or non ionic polysaccharides. On

hydrolysis gums yield sugar and salts of uronic acid¹⁰.

Guar gums: It is a naturally occurring galactomannan polysaccharide; consists of chiefly high molecular weight hydrocolloidal polysaccharide, composed of galactan and mannan units combined through glycosidic linkages and shows degradation in the large intestine due the presence of microbial enzymes¹¹. Guar gum is hydrophilic and swells in cold water, forming viscous colloidal dispersions or sols. This gelling property retards release of the drug from the dosage form, making it more likely that degradation will occur in the colon. Guar gum was found to be a colon-specific drug carrier in the form of matrix and compression-coated tablets as well as microspheres¹¹. Guar gum-based matrix tablets of rofecoxib were prepared for their intended use in the chemoprevention of colorectal cancer¹².

Locust Bean Gum: It is also called carob gum, as it is derived from carob (*Ceratonia siliqua*) seeds. This neutral polymer is only slightly soluble in cold water; it requires heat to achieve full hydration and maximum viscosity. Cross-linked galactomannan however led to water-insoluble film forming product-showing degradation in colonic microflora¹³.

Karaya gum: Karaya gum is obtained from *Sterculia urens* (Family sterculiaceae) is a partially acetylated polymer of galactose, rhamnose, and glucuronic acid¹³. Park et al. showed that mucoadhesive tablets prepared by karaya gum for buccal delivery, had superior adhesive properties as compared to guar gum and was able to provide zero-order drug release, but concentrations greater than 50 % w/w may be required to provide suitable sustained release¹⁵.

Albizia gum: Albizia gum is obtained from the incised trunk of the tree *Albizia zygia* (DC) J. F. Macbr, family Leguminosae and is shaped like round elongated tears of variable color ranging from yellow to dark brown. It consists of β -1–3-linked D-galactose units with some β 1-6-linked Dgalactose units. The genus *Albizzia* containing some twenty-six species is a member of the Mimosacez, a family which also includes the gum-bearing genera *Acacia* and *Prosopis*. Only two species of *Albizia*, *A. zygia* and *A. sassa*, are however, known to produce gum. *Albizia* gum has been investigated as a possible substitute for gum Arabic as a natural emulsifier for food and pharmaceuticals^{16, 17}.

Xanthan gum: Xanthan gum is a high molecular weight extra cellular polysaccharide produced by the fermentation of the gram-negative bacterium *Xanthomonas campestris*. The anionic character of this polymer is due to the presence of both glucuronic acid and pyruvic acid groups in the side chain¹⁸. In one of the trials, xanthan gum showed a higher ability to retard the drug release than synthetic hydroxypropylmethylcellulose. Xanthan gum and hydroxypropylmethylcellulose were used as hydrophilic matrixing agents for preparing modified release tablets of diltiazem HCl. The amount of hydroxypropylmethylcellulose and xanthan gum exhibited significant effect on drug release from the tablets prepared by direct compression technique. It was concluded that by using a suitable blend of hydroxypropylmethylcellulose and xanthan gum desired modified drug release could be achieved¹⁹.

Starches: It is the principal form of carbohydrate reserve in green plants and especially present in seeds and underground organs. Starch occurs in the form of granules (starch grains), the shape and size of which are characteristic of the species,

as is also the ratio of the content of the principal constituents, amylose and amylopectin. A number of starches are recognized for pharmaceutical use. These include maize (*Zea mays*), rice (*Oryza sativa*), wheat (*Triticum aestivum*), and potato (*Solanum tuberosum*)²⁰. To deliver proteins or peptidic drugs orally, microcapsules containing a protein and a proteinase inhibitor were prepared. Starch/bovine serum albumin mixed-walled microcapsules were prepared using interfacial cross-linking with terephthaloyl chloride. The microcapsules were loaded with native or amino-protected aprotinin by incorporating protease inhibitors in the aqueous phase during the cross-linking process. The protective effect of microcapsules with aprotinin for bovine serum albumin was revealed in vitro²¹.

Alginates: Alginates are linear polymers that have 1-4'linked β -D-mannuronic acid and α -L-guluronic acid residue arranged as blocks of either type of unit or as a random distribution of each type. A Eudragit L-30D-coated calcium alginates bead for colonic delivery of 5-aminosalicylic acid has been reported²². Different enteric as well as sustained release polymers were applied as coat on calcium alginate beads. A system was prepared by coating calcium alginate beads with Aquacoat[®] that is a pH-independent polymer followed by 2 % w/w coating of Eudragit L-30D. Being enteric polymer, Eudragit[®] resisted the release of drug in acidic media and drug release was triggered at alkaline pH and controlled by thickness of Aquacoat[®]. When drug-loaded calcium alginate beads swell sufficiently (osmotic gradient) to exceed the strength of outer sustained released coat, the film bursts to release the drug. Such a system delivers drug to the distal intestine with minimal initial leak and provides sustained release in the colon²³.

Inulin: Insulin is a naturally occurring storage polysaccharide found in many plants such as onion, garlic, artichoke, and chicory. Most of these fructose chains have a glucose unit as the initial moiety. It is not hydrolyzed by the endogenous secretions of the human digestive tract²⁴. However, bacteria harboring in the colon and more specifically Bifidobacteria are able to ferment inulin²⁵.

REFERENCE:

1. Englyst HN. Digestion of the polysaccharides of potato in the small intestine of man. *Am J Clin Nutr* 1987; 45: 423-431.
2. Giunchedi P, Conte U, Chetoni P, Saettone MF. Pectin microspheres as ophthalmic carriers for piroxicam: Evaluation in vitro and in vivo in albino rabbits. *Eur J Pharm Sci* 1999; 9: 1-7.
3. Rubinstein A, Radai R, Ezra M, Pathak S, Rokem JM. In vitro evaluation of calcium pectinate: A potential colon-specific drug delivery carrier. *Pharm Res* 1993; 10: 258-263.
4. Musabayane CT, Munjeri O, Matavire TP. Transdermal delivery of chloroquine by amidated pectin hydrogel matrix patch in the rat. *Ren Fail* 2003; 25: 525-34.
5. Cheng K, Lim LY. Insulin-loaded calcium pectinate nanoparticles: Effects of pectin molecular weight and formulation pH. *Drug Develop Ind Pharm* 2004; 30: 359-67.
6. Tozaki H, Odoriba T, Okada N, Fujita T, Terabe A, Suzuki T, Okabe S, Murnishi S, Yamamoto A. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. *J Control Res* 2002; 82: 51-61.
7. Sinha VR, Singla AK, Wadhawan S, et al. Chitosan microspheres as a potential carrier for drugs. *Int J Pharm* 2004; 274: 1-33.

8. Kokate CK, Purohit AP, Gokhale SB, editors. Pharmacognosy, India: Nirali Prakashan 2003; 22 nd ed 133-66.
9. Tomolin J, Taylor JS, Read NW. The effect of mixed faecal bacteria on a selection of viscous polysaccharide in vitro. *Nutr Rep Int* 1989; 39,121-135.
10. Bayliss CE, Houston AP. Degradation of guar gum by faecal bacteria. *Appl Environ Microbiol* 1986; 48: 626-632.
11. Macfarlane GT, Hay S, Macfarlane S, Gibson GR. Effect of different carbohydrates on growth polysaccharidases and glycosidase production of *Bacteroides ovatus* in batch and continuous culture. *J. Appl. Bacteriol.* 1990; 68: 179-187.
12. Al-Saidan SM, Krishnaiah YS, Patro SS, Satyanaryana V. In vitro and in vivo evaluation of guar gum matrix tablets for oral controlled release of water-soluble diltiazem hydrochloride. *AAPS PharmSciTech* 2005; 6:E14-21.
13. Park CR, Munday DL. Evaluation of selected polysaccharide excipients in buccoadhesive tablets for sustained release of nicotine. *Drug Develop Ind Pharm* 2004; 30: 609-17.
14. Ashton WA, Jefferies M, Morley RG, Pass G, Phillips GO, Power DMJ. Physical properties and applications of aqueous solutions of *Albizia zygia* gum. *J Sci Food Agric* 1975; 26: 697-704
15. US National Academy of Sciences Tropical legumes. National Academy of Sciences, Washington, DC. 1979.
16. Odeku OA, Fell JT. In-vitro evaluation of khaya and albizia gums as compression coatings for drug targeting to the colon. *J Pharm Pharmacol* 2005; 57: 163-168.
17. Bhardwaj TR, Kanwar M, Lal R, Gupta A. Natural gums and modified natural gums as sustained-release carriers. *Drug Develop Ind Pharm* 2000; 26: 1025-38.
18. Trease GE, Evans WC editors. Text Book of Pharmacognosy, London: Balliere, Tindall; 2002; 15 th ed.
19. Shun YL, Ayres JW. Calcium alginate beads as core carriers of 5-aminosalicylic acid. *Pharm Res* 1992; 9: 714Y790.
20. McIntosh M, Stone BA, Stanisich VA. Curdlan and other bacterial (1-3)- beta- D-glucans. *Appl Microbiol Biotechnol* 2005; 68: 163-173.
21. Dysseler BS, Hoffen MJ. Inulin, an alternative dietary fiber. Properties and quantitative analysis. *Eur J Clin Nutr* 1995; 49: S145-S152.
22. Keller C, Modler RC, Metabolism of fructooligosaccharides by *Bifidobacterium* spp. *Appl Microbiol Biotechnol* 1989; 31: 537-541.
23. Wang X, Gibson GR. Effects of the in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine. *J Appl Bacterol* 1993; 75: 373-380.
24. Gibson GR, Roberfroid MR. Dietary modulation of the human colonic microflora, introducing the concept of prebiotics. *J Nutr* 1995; 125: 1401-1414.
25. Vervoort L, Kinget R. In vitro degradation by colonic bacteria of inulin HP incorporated in Eudragit films. *Int J Pharm* 1996; 129: 185-190.

Corresponding Author: Mohit Khandelwal

Journal: The Pharma Innovation

Website: www.thepharmajournal.com

Volume: 1

Issue: 1

Year: 2012

Page no.: 9- 13
